Expression analysis of BDNF, BACE1 and their antisense transcripts in inflammatory demyelinating polyradiculoneuropathy

Ghafouri‐Fard, Soudeh; Mazdeh, Mehrdokht; Nicknafs, Fwad; Nazer, Naghme; Sayad, Arezou; Taheri, Mohammad

doi:10.1016/j.msard.2020.102613

Cited by 3 publications

(5 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Long non-coding RNAs (lncRNAs) have central influences on the activity of immune system 7 , 8 . Contribution of a number of these transcripts in the pathogenesis of CIDP and GBS has been recently verified by our group 9 . However, the role of several members of lncRNAs in autoimmune neuropathies needs to be elucidated.…”

Section: Introductionmentioning

confidence: 63%

Dysregulation of lncRNAs in autoimmune neuropathies

Gholipour

Taheri

Habibabadi

et al. 2021

Sci Rep

Self Cite

View full text Add to dashboard Cite

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and Guillain-Barré syndrome (GBS) are inflammatory neuropathies with different clinical courses but similar underlying mechanisms. Long non-coding RNAs (lncRNAs) might affect pathogenesis of these conditions. In the current project, we have selected HULC, PVT1, MEG3, SPRY4-IT1, LINC-ROR and DSCAM-AS1 lncRNAs to appraise their transcript levels in the circulation of CIDP and GBS cases versus controls. Expression of HULC was higher in CIDP patients compared with healthy persons (Ratio of mean expression (RME) = 7.62, SE = 0.72, P < 0.001). While expression of this lncRNA was not different between female CIDP cases and female controls, its expression was higher in male CIDP cases compared with male controls (RME = 13.50, SE = 0.98, P < 0.001). Similarly, expression of HULC was higher in total GBS cases compared with healthy persons (RME = 4.57, SE = 0.65, P < 0.001) and in male cases compared with male controls (RME = 5.48, SE = 0.82, P < 0.001). Similar pattern of expression was detected between total cases and total controls. PVT1 was up-regulated in CIDP cases compared with controls (RME = 3.04, SE = 0.51, P < 0.001) and in both male and female CIDP cases compared with sex-matched controls. Similarly, PVT1 was up-regulated in GBS cases compared with controls (RME = 2.99, SE = 0.55, P vale < 0.001) and in total patients compared with total controls (RME = 3.02, SE = 0.43, P < 0.001). Expression levels of DSCAM-AS1 and SPRY4-IT1 were higher in CIDP and GBS cases compared with healthy subjects and in both sexes compared with gender-matched healthy persons. Although LINC-ROR was up-regulated in total CIDP and total GBS cases compared with controls, in sex-based comparisons, it was only up-regulated in male CIDP cases compared with male controls (RME = 3.06, P = 0.03). Finally, expression of MEG3 was up-regulated in all subgroups of patients versus controls except for male GBS controls. SPRY4-IT could differentiate CIDP cases from controls with AUC = 0.84, sensitivity = 0.63 and specificity = 0.97. AUC values of DSCAM-AS1, MEG3, HULC, PVT1 and LINC-ROR were 0.80, 0.75, 0.74, 0.73 and 0.72, respectively. In differentiation between GBS cases and controls, SPRY4-IT and DSCAM-AS1 has the AUC value of 0.8. None of lncRNAs could appropriately differentiate between CIDP and GBS cases. Combination of all lncRNAs could not significantly enhance the diagnostic power. Taken together, these lncRNAs might be involved in the development of CIDP or GBS.

show abstract

Section: Introductionmentioning

confidence: 63%

Dysregulation of lncRNAs in autoimmune neuropathies

Gholipour

Taheri

Habibabadi

et al. 2021

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…We screened 2216 nonduplicated records, resulting in 36 studies 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 being included after eligibility assessment, including 2301 patients with peripheral neuropathy and 2113 control participants ( Figure 1 ). Participant characteristics are detailed in eTable 2 in Supplement 1 .…”

Section: Resultsmentioning

confidence: 99%

“…Participant characteristics are detailed in eTable 2 in Supplement 1 . The most commonly reported type of peripheral neuropathy was diabetic neuropathy (13 studies 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 ), followed by Charcot-Marie-Tooth disease (6 studies 34 , 35 , 36 , 37 , 38 , 39 ), Guillain-Barre Syndrome (6 studies 26 , 40 , 41 , 42 , 43 , 44 ), chronic inflammatory demyelinating polyneuropathy (5 studies 26 , 34 , 45 , 46 , 47 ), acute inflammatory demyelinating polyneuropathy (3 studies 26 , 34 , 45 ), and hereditary transthyretin-mediated amyloidosis with polyneuropathy (3 studies 48 , 49 , 50 ). Single studies included hexane-induced neuropathy, 51 critical illness polyneuropathy, 52 acute motor axonal neuropathy, 34 axonal sensorimotor neuropathy, 26 vasculitic neuropathy, 53 rheumatoid arthritis with neuropathy, 54 leprosy with neuropathy, 55 and a cohort including various neuropathies 56 ( Table ).…”

Section: Resultsmentioning

confidence: 99%

“…From all studies, we identified 16 different blood-based biomarkers associated with nerve involvement measured in either serum or plasma. Neurofilament light chain (NFL) was the most studied biomarker (17 studies 32 , 33 , 35 , 37 , 38 , 39 , 40 , 41 , 43 , 46 , 47 , 48 , 49 , 50 , 52 , 53 , 56 ), followed by 3 studies each for brain-derived neurotrophic factor, 22 , 30 , 45 S100B, 21 , 33 , 55 and neuron-specific enolase. 25 , 28 , 33 Biomarkers from 2 studies included nerve growth factor, 27 , 30 neural cellular adhesion molecule, 26 , 34 glial fibrillary acidic protein, 23 , 52 transmembrane protease serine 5, 38 , 39 and neurofilament heavy chain 29 , 36 ( Table ).…”

Section: Resultsmentioning

confidence: 99%

“…We screened 2216 nonduplicated records, resulting in 36 studies being included after eligibility assessment, including 2301 patients with peripheral neuropathy and 2113 control participants (Figure 1). Participant characteristics are detailed in eTable 2 in Supplement 1.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Types and Concentrations of Blood-Based Biomarkers in Adults With Peripheral Neuropathies

et al. 2022

View full text Add to dashboard Cite

ImportancePeripheral neuropathies are common conditions and can result in numbness, paresthesia, motor deficits, and pain. There is increasing evidence for the use of biomarkers as clinical indicators of the presence, severity, and prognosis of nerve lesions; however, biomarker identification has largely been focused on disorders of the central nervous system, and less is known about their role in the peripheral nervous system.ObjectiveTo assess blood-based biomarker concentrations associated with nerve involvement in patients with peripheral neuropathy compared with control participants.Data SourcesOvid, MEDLINE, Embase, and CINAHL were searched from inception to September 23, 2021.Study SelectionObservational studies reporting on blood biomarkers in patients diagnosed with peripheral neuropathy were included. This review was preregistered on PROSPERO and followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline. Data were abstracted by 1 investigator and independently reviewed by a second.Data Extraction and SynthesisData were meta-analyzed when at least 2 studies reported the same biomarker with comparable methodology. Fixed-effects models were used when only 2 studies were included; random-effects models were used when more than 2 studies were included.Main Outcomes and MeasuresThe outcome of interest was concentration of biomarkers.ResultsThis review included 36 studies reporting on 4414 participants, including 2113 control participants and 2301 patients with peripheral neuropathy with 13 distinct peripheral neuropathy diagnoses. Diabetic neuropathy was the most common neuropathy diagnosis (13 studies), followed by Charcot-Marie-Tooth disease (6 studies) and Guillain-Barre syndrome (6 studies). Overall, 16 different blood-based biomarkers associated with nerve involvement were evaluated. The most used were neurofilament light chain, S100B, brain-derived neurotrophic factor, and neuron-specific enolase. Patients with peripheral neuropathy demonstrated significantly higher levels of neurofilament light chain compared with controls (standardized mean difference [SMD], 0.93 [95% CI, 0.82 to 1.05]; P &lt; .001). There were no significant differences in levels of S100B (SMD, 1.10 [95% CI, −3.08 to 5.28]; P = .38), brain-derived neurotrophic factor (SMD, −0.52 [95% CI, −2.23 to 1.19]; P = .40), or neuron-specific enolase (SMD, −0.00 [95% CI, −1.99 to 1.98]; P = .10) in patients with peripheral neuropathy compared with control participants.Conclusions and RelevanceThe findings of this systematic review and meta-analysis support the use of neurofilament light chain as a blood-based measure associated with the presence of neuronal injury in patients with peripheral neuropathy.

show abstract